Biomerica announced it has secured its first commercial order for its Hp Detect™ H. pylori stool antigen test from a major European laboratory chain, covering the United Kingdom market. The order follows the company’s February 2026 MHRA registration and positions the product as a reference account that could accelerate further distribution across the EU.
The deal marks a critical transition from regulatory approval to revenue generation for the Hp Detect™ platform. While the order’s monetary value and volume are not disclosed, the partnership signals confidence from a large testing network and provides Biomerica with a tangible foothold in a market where H. pylori infection affects roughly 45% of Europeans and is classified by the WHO as a Class 1 carcinogen.
Biomerica’s financial performance remains under pressure. In the second quarter of fiscal 2026 (ended November 30 2025), the company reported a net loss of $1.32 million on net sales of $1.21 million, a decline from the prior year. Management has expressed substantial doubt about the company’s ability to continue as a going concern without additional financing, underscoring the importance of new commercial revenue streams.
CEO Zack Irani said the partnership “will grow as Hp Detect™ becomes embedded in their routine testing workflow” and that the reference account will help the company pursue additional U.S. and European distribution agreements. The statement reflects a strategic focus on scaling the product’s adoption beyond the initial UK launch.
The Hp Detect™ test has already achieved FDA 510(k) clearance and CE marking, and its clinical performance shows 99 % positive and 98 % negative percent agreement with an FDA‑cleared device, as well as 100 % sensitivity and specificity four weeks after eradication therapy. These credentials support the product’s marketability in both the U.S. and EU.
While the first commercial order is a positive milestone, the company’s ongoing losses and the lack of disclosed order size mean that the impact on cash flow and long‑term viability remains uncertain. Biomerica will need to secure additional orders and potentially additional financing to move from a regulatory‑approved product to a profitable business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.